Preclinical & Translational

Chair: Rakesh Dixit, President & Chief Executive Officer, Bionavigen Oncology

Download the Full Event Guide for full details

Assessing ADC Non-Clinical PK/PD to Characterise ADC Mechanism & Predict Clinical Activity

11.30 am A Translational Approach to ADC Evaluation: From In Vitro Organoids to Advanced In Vivo Models

• Exploring the assessment of ADC efficacy through single-mouse in vitro PDXO, MiniPDX, PDX, and clinical MiniPDX models
• Demonstrating how models bridge preclinical findings to clinical indications, offering insights into drug efficacy and resistance
• Highlighting the integration of diverse models to accelerate ADC development and guide decision-making in pharmaceutical R&D

Simon Jiang, Vice President, Biology & Head, Scientific Engagement, Lide Biotech

12.00 pm Exploring Preclinical Characterisation of pH Dependent AnticMET ADC MYTX-011 Designed for Enhanced Tumour Delivery

• Outlining rationale and engineering of MYTX-011, a cMET targeting ADC
• Assessing comprehensive preclinical in vitro and in vivo characterisation in various animal models
• Evaluating MYTX-011 PK data and safety in non-human primates

Nimish Gera, Vice President, Biologics, Mythic Therapeutics

12.30 pm Hacking the Tumour Matrix: Non-Invasive Extracellular Matrix (ECM) Biomarkers for ADC Drug Development

• Sharing how dysregulated ECM remodelling in cancer leads to the release of specific ECM turnover fragments into the bloodstream
• Discussing the doubling ADC response rates with PRO-C3: Harnessing non-Invasive ECM biomarkers for enhanced tumour drug delivery
• Outlining how specific ECM-derived cleavage products have the potential to predict ADC linker cleavage, and drug release within tumours

Nicholas Willumsen, Director & Head, Oncology, Nordic Bioscience

1.00 pm Lunch & Learn Session: From Molecule to Market: Comprehensive CDMO Services for ADC and Bioconjugation Presented By

Invite only session

Diving into Translational Development of Novel ADC Linker-Payload Designs

2.00 pm Next Generation XDCs with Wider Therapeutic Window, Better Preclinical Translation & Higher Affordability
•Proprietary One-Enzyme-One-Reaction platform (Organic free, Super stability, ADCC depletion without Fc engineering, etc., diversified linker-payload toolbox)
•Robust and homogeneous dual payload platform
• The world's first ADC high-throughput screening platform, iDiscovery, revolutionizes PCC selection from "By Design" to "By Screening”
• The world's first ADC GMP manufacturing process in a mAb facility, iConjugator, significantly improves cost-effectiveness in CMC

Wenchao Hong, Vice President, Business Development, GeneQuantum Healthcare

2.30 pm Evaluating Comprehensive Preclinical Development of IKS04: the First Anti-CA242 Ultra-Low DAR ADC Against Solid Tumours

• Introducing IKS04 ultra-low DAR approach co-dosed with antibodies
• Applying concepts of increased tumour penetration to highly potent PBDnprodrug payloads
• Reviewing the preclinical profile of IKS04 targeting GI solid tumours and highlighting future plans for clinical investigation

Jutta Deckert, Vice President, Research & Development, Iksuda Therapeutics

3.00 pm Broad-Spectrum Efficacy of
CEACAM6-Targeted ADC With BET
Protein Degrader

• Developing a novel ADC targeting CEACAM6 with BET protein degrader
• Demonstrating potent and broad spectrum efficacy in CRC, BC, and LC models
• Discussing combination therapy effects
with immune checkpoint inhibitors

Hiroyuki Kogai, Scientist, Eisai

Clinical Lessons

Chair: Gilles Gallant, Chief Development Officer, Mythic Therapeutics

Download the Full Event Guide for full details

Breaking Down Emerging ADC Translational Profiles to Understand What Makes a Clinically Effective ADC

11.30 am Assessing Safety & Tolerability of MYTX-011, a cMET ADC in the Phase 1 KisMET-01 Study

• Reviewing the safety and tolerability of c-MET targeting agents focusing on c-MET ADCs
• Explaining MYTX-011 preclinical data and performance
• Describing the safety profile of MYTX-011 in a dose escalation first-in-human Phase 1 NSCLC study

Gilles Gallant, Chief Development Officer, Mythic Therapeutics

12.00 pm Applying Learnings From Clinical Development of SQ3370 to Optimise Development of Novel Tumour-Targeted Therapies

• Discussing safety and efficacy results from the phase 2 clinical programme of SQ3370
• Reviewing learnings from the clinical study and how they have informed design principles going forward
• Highlighting data from Shasqi’s lead asset targeting CEACAM5

Travis Biechele, Vice President, Research, Shasqi

12.30 pm PDL1V (PF-08046054): A Firstin- Class PD-L1-Directed ADC with Promising Activity in 2L+ NSCLC

• PDL1V was engineered for enhanced potency through increased internalization and payload delivery
• PDL1V is efficacious across a broad range of PD-L1 expression & induces MMAE-mediated immune activation in vivo
• Interim results of a phase 1 Study of PDL1V in patients with PDL1-expressing solid tumours demonstrate promising activity in 2L+ NSCLC

Garrett Cornelison, Senior Principal Scientist, Pfizer

1.00 pm Lunch & Learn Session: From Molecule to Market: Comprehensive CDMO Services for ADC and Bioconjugation Presented By

Invite only session

Showcasing & Contextualising Cutting-Edge ADC Clinical
Performance & Trial Design

2.00 pm Cross Border Mindset as a Key Success Factor for Rapid & High-Quality Clinical Development of ADCs

• What is different in the development of an ADC as opposed to other molecules, and why does it matter?
• Evaluating cross-border mindset and partnerships as key tools to accelerate clinical development of ADCs
• Exploring case studies of ADC clinical development

Maria Dahl, Chief Operating Officer & Head, Europe, Innovent Biologics

2.30 pm Summary Discussion: Understanding Clinical Performance of ADCs & Assessing Opportunities for Biomarker & Patient Selection Tools

Join this closing summary with clinical and medical speakers and attendees to summarise the learnings from the past two days of content. Make sure to bring your questions you haven’t had the chance to ask across ADCs progression to earlier-line treatments, clinical pharmacology, and dose optimisation, and biomarkers for precision medicine ADC development

Gilles Gallant, Chief Development Officer, Mythic Therapeutics

3.00 pm Clinical Lessons Stream Closes

Process & Analytical Development

Chair: Paul Wolstenholme-Hogg, Vice President, Medicinal Chemistry, ADC Therapeutics

Download the Full Event Guide for full details

Navigating Development & Validation of Biological Assays to Assess ADC Properties

11.30 am Detailing Bioassay Development
& Applications in ADC Characterisation & Lot Release

• Exploring bioassays in place to support ongoing ADC development and characterisation
• Looking to the future – how much more can bioassays be used for ADC analysis?
• Explaining how bioassays fit into lot release and process

Uchechukwu Okorji-Obike, Senior Scientist, Bioassay Development, AstraZeneca

12.00 pm Intact Mass Analysis to Investigate In Vitro & In Vivo ADC Properties

• Leveraging hybrid immunocapture and HR-MS methods to assess ADC properties
• Investigating applications for in vivo DAR determination
• Investigating ADC stability characterisation

Federico Riccardi Sirtori, Director & Head, NBE-DMPK Innovative Bioanalytics, Merck KGaA

12.30 pm Antibody Drug Conjugates From a Bioanalytical Lab’s Perspective: LBA & LCMSMS Two Different Solutions for Similar Questions

• Unveiling the diverse and complex bioanalytical dataset needs for successful development of ADCs – the BA lab as a key partner
• Exploring approaches and types of data using LBA assays
• Explaining approaches and types of data using mass spectrometric assays

Daniel Schulz-Jander, Senior Director, Bioanalysis (Mass Spectrometry), QPS

1.00 pm Lunch & Learn Session: From Molecule to Market: Comprehensive CDMO Services for ADC and Bioconjugation Presented By

Invite only session

Controlling ADC Process Through In-Depth Knowledge of Process Analytical Technologies

2.00 pm Residual Toxin Removal: Scale & Phase Appropriate Approaches & Challenges

• Using three model ADCs with variability in toxin-linker properties to explore residual toxin removal methods and their applicability across a set of key toxin classes
• Assessing challenges in residual toxin removal change from discovery to manufacturing
• Evaluating approaches to improving ADC quality with residual toxin removal

Alisdair Hearn, Senior Process Development Scientist, Sterling Pharma Solutions

2.30 pm Summary Discussion: Brainstorming the Barriers & Strategies to Improve ADC Product Quality & Yield

Join this closing discussion session with your fellow speakers and attendees to break down the learnings from the past two days. Covering challenges in optimising ADC quality and yield, impurity control, and streamlining ADC bioassay development, this is your opportunity to share your thoughts and ask the speakers' final burning questions.

Paul Wolstenholme-Hogg, Vice President, Medicinal Chemistry, ADC Therapeutics

3.00 pm Process & Analytical Development Stream Close

Manufacturing & Supply Chain

Download the Full Event Guide for full details

Maintaining & Upgrading ADC Manufacturing Under Accelerated Clinical Timelines

11.30 am Accelerating HPAPI & ADC Manufacturing Process Optimization with Artificial Intelligence

• Leveraging AI to advance clinical and commercial manufacturing processes
• Presenting case studies that highlight AI predictions paired with experimental validation
• Introducing an innovative alternative to traditional empirical/heuristic PRD approaches

Rohtash Kumar, Senior Vice President, Development Operations & Chief Technology Officer, Veranova

12.00 pm Managing CMC Challenges & Capabilities Across Complex ADC Supply Chain

• Evaluating challenges and opportunities in ADC development and CMC
• Exploring CMC strategy across ADC components: drug-linker, mAbs, DS and DP
• Highlighting strategies for effective ADC manufacturing supply chain

Francois D’Hooge, Tech Management Lead, ADC Drug Substance, Daiichi Sankyo

Meike Roskamp, Director, Bioconjugation, Daiichi Sankyo

12.30 pm Mastering the Complexity of ADC
Development: Expertise That Delivers

• mAbs and bioconjugates capabilities and services
• Case studies: reduction and conjugation optimization
• Case studies: mAb and ADC purification improvement

Matthieu Culié, Head, mAb & ADC Development & GMP Manufacturing, GTP Bioways

12.45 pm Manufacturing & Supply Chain Stream Closes for Lunch

1.00 pm Lunch & Learn Session: From Molecule to Market: Comprehensive CDMO Services for ADC and Bioconjugation Presented By

Invite only session

Exploring ADC Best Practices & Strategy for Safe Manufacturing at Scale

2.00 pm Integrating Highly Potent Drug Safety Into ADC Development & Manufacturing

• Integrating HPAPI Occupational Health and Safety within ADC manufacturing projects – getting the strategic decisions right
• Exploring ADC component hazard assessments (occupational toxicology) and risk assessments across targeting moieties and payloads
• Covering API Containment and Control in all ADC working environments

Justin Mason-Home, Director, HPAPI Project Services Limited

2.30 pm Summary Discussion: Breaking Down the Top Opportunities to Overcome ADC Manufacturing & Supply Chain Bottlenecks

Join this closing roundtable session with leaders in the ADC CMC field to break down the key learnings from the two days of presentations and discussion. With your fellow speakers and attendees, discuss, debate and evaluate the opportunities and challenges in ADC manufacturing timelines, navigating supply with multiple outsourcing partners, technology transfer and scale-up, and more.

William Olughu, Senior Principal Scientist, Ipsen

3.00 pm Manufacturing & Supply Chain Stream Closes